Year: 2026
Type: article
Study design: Systematic Review
Abstract: Rosai-Dorfman disease (RDD) was long regarded as a reactive histiocytic proliferation, consistent with its frequent spontaneous regression and the absence of identified clonal drivers. This view began to shift in 2016–2017, when recurrent activating mutations in KRAS and MAP2K1 were identified in a subset of cases, prompting partial reclassification of RDD as a clonal neoplasm. This review synthesises the genetic and genomic testing literature in RDD published 2014–2025, drawing on nineteen cohort studies and conference abstracts identified through a structured PubMed search and citation chaining. Reported mutation-positive rates range from 0% to approximately 83% depending on cohort, sequencing method, and anatomic site, with KRAS and MAP2K1 the most frequently implicated genes. Cutaneous disease shows a distinct NRAS -dominant profile, while intraosseous disease trends toward mutation negativity, though each rests upon a few cohorts. Beyond MAPK, recurrent findings in CSF1R and other receptor tyrosine kinases, alongside a scattered catalog of epigenetic and myeloid-malignancy-associated alterations, indicate that the genomic landscape extends beyond one pathway. Population data remain sparse: Saudi and Japanese cohorts diverge from the North American and Chinese literature dominating this field, but neither is large enough to establish a stable population-level profile. Small samples, heterogeneous platforms, inconsistent testing completeness, and few prospective multi-center cohorts limit how confidently mutation rates can be generalised. This review discusses the competing reactive and neoplastic interpretations of RDD, the concepts needed to interpret its genomic data, and emerging diagnostic and genotype-informed therapeutic developments. RDD is best understood as a genomically defined clonal subset within a broader, poorly characterised population, not a disease fully reclassified from reactive to neoplastic. Prospective, uniformly sequenced, multi-institutional studies including underrepresented populations are needed to resolve this picture.
Source: Frontiers in Oncology
Author: Sarah Binhassan
Institution: King Saud University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234552516
